{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:19:04Z","timestamp":1785777544552,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02676-7","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:19:22Z","timestamp":1748488762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER"],"prefix":"10.1038","volume":"15","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2676_CR1","doi-asserted-by":"crossref","unstructured":"Eng, C. et al. A Comprehensive Framework for early-onset Colorectal cancer Research (The Lancet Oncology, 2022).","DOI":"10.1016\/S1470-2045(21)00588-X"},{"key":"2676_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA: A Cancer. J. Clin. 74, 12\u201349 (2024).","journal-title":"J. Clin."},{"key":"2676_CR3","first-page":"252","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. CA: A Cancer. J. Clin. 64, 252\u2013271 (2014).","journal-title":"J. Clin."},{"key":"2676_CR4","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer. J. Clin. 69, 363\u2013385 (2019).","journal-title":"J. Clin."},{"key":"2676_CR5","doi-asserted-by":"crossref","unstructured":"Sebag-Montefiore, D. et al. Preoperative Radiotherapy Versus Selective Postoperative Chemoradiotherapy in Patients with Rectal cancer (MRC CR07 and NCIC-CTG C016): a Multicentre, Randomised Trial (The Lancet, 2009).","DOI":"10.1016\/S0140-6736(09)60484-0"},{"key":"2676_CR6","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median Follow-Up of 11 years. J. Clin. Oncol. 30, 1926\u20131933 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2676_CR7","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar, J. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J. Clin. Oncol. 40, 2546\u20132556 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2676_CR8","doi-asserted-by":"crossref","unstructured":"Sauer, R. et al. Preoperative Versus Postoperative Chemoradiotherapy for Rectal cancer (The New England Journal of Medicine, 2004).","DOI":"10.1056\/NEJMoa040694"},{"key":"2676_CR9","doi-asserted-by":"crossref","unstructured":"Akgun, E. et al. The Effects of Chemoradiotherapy on Recurrence and Survival in Locally Advanced Rectal Cancers with Curative Total Mesorectal Excision: a Prospective, Nonrandomized Study (World Journal of Surgical Oncology, 2017).","DOI":"10.1186\/s12957-017-1275-4"},{"key":"2676_CR10","unstructured":"Martling, A. et al. Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. Br. J. Surg., (2016)."},{"key":"2676_CR11","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.3748\/wjg.v24.i40.4586","volume":"24","author":"T-H Wang","year":"2018","unstructured":"Wang, T-H. et al. Second primary malignancy risk after radiotherapy in rectal cancer survivors. World J. Gastroenterol. 24, 4586\u20134595 (2018).","journal-title":"World J. Gastroenterol."},{"key":"2676_CR12","doi-asserted-by":"crossref","unstructured":"Rombouts, A. J. M. et al. Incidence of Second Tumors after Treatment with or Without Radiation for Rectal cancer (Annals of Oncology, 2017).","DOI":"10.1093\/annonc\/mdw661"},{"key":"2676_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2024.02.013","volume":"63","author":"C McPartland","year":"2024","unstructured":"McPartland, C. et al. Risk of secondary malignancies after pelvic radiation: A Population-based analysis. Eur. Urol. Open. Sci. 63, 52\u201361 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"key":"2676_CR14","doi-asserted-by":"crossref","unstructured":"Okajima, K. et al. Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy. Int. J. Clin. Oncol., (2012).","DOI":"10.1007\/s10147-012-0496-3"},{"key":"2676_CR15","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Incidence and Associated Factors of Developing Second Pelvic Malignant Neoplasms among Prostate cancer Patients Treated with Radiotherapy (Frontiers in Oncology, 2023).","DOI":"10.3389\/fonc.2023.1260325"},{"key":"2676_CR16","doi-asserted-by":"crossref","unstructured":"Adjei Boakye, E. et al. Risk of Second Primary Cancers among Survivors of Gynecological Cancers (Gynecologic Oncology, 2020).","DOI":"10.1016\/j.ygyno.2020.06.492"},{"key":"2676_CR17","doi-asserted-by":"crossref","unstructured":"Mukand, N. H. et al. Abstract C020: Racial Differences in the Risks of Second Primary Gynecologic Cancers Following Chemotherapy for Malignant Ovarian Tumors: Asian Subgroups in the United States, 2000\u20132016 (Cancer Epidemiology Biomarkers & Prevention, 2020).","DOI":"10.1158\/1538-7755.DISP19-C020"},{"key":"2676_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-021-00486-w","volume":"18","author":"VK Reddy","year":"2021","unstructured":"Reddy, V. K. & Vapiwala, N. Secondary malignancy after radiotherapy: not always a secondary concern. Nat. Reviews Urol. 18, 513\u2013514 (2021).","journal-title":"Nat. Reviews Urol."},{"key":"2676_CR19","doi-asserted-by":"crossref","unstructured":"Shiota, M. et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. J. Clin. Oncol., (2015).","DOI":"10.18632\/oncotarget.3817"},{"key":"2676_CR20","first-page":"345","volume":"37","author":"A de la Taille","year":"2003","unstructured":"de la Taille, A. & Zerbib, M. Complications urologiques de La radioth\u00e9rapie. Ann. Urol. (Paris). 37, 345\u2013357 (2003).","journal-title":"Ann. Urol. (Paris)"},{"key":"2676_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.21037\/tcr-20-2589","volume":"10","author":"J Chorbi\u0144ska","year":"2021","unstructured":"Chorbi\u0144ska, J., Krajewski, W. & Zdrojowy, R. Urological complications after radiation therapy\u2014nothing ventured, nothing gained: a narrative review. Translational Cancer Res. 10, 1096\u20131118 (2021).","journal-title":"Translational Cancer Res."},{"key":"2676_CR22","doi-asserted-by":"crossref","unstructured":"Liang, F. et al. Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies. BMC Cancer 17, (2017).","DOI":"10.1186\/s12885-017-3902-4"},{"key":"2676_CR23","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/ijc.33361","volume":"148","author":"RS Allodji","year":"2020","unstructured":"Allodji, R. S. et al. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: an international pooled analysis. Int. J. Cancer. 148, 2079\u20132089 (2020).","journal-title":"Int. J. Cancer"},{"key":"2676_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10147-019-01430-0","volume":"24","author":"J-L Wei","year":"2019","unstructured":"Wei, J-L., Jiang, Y-Z. & Shao, Z-M. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int. J. Clin. Oncol. 24, 934\u2013940 (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"2676_CR25","doi-asserted-by":"crossref","unstructured":"Yuan, Y. et al. Risk of second primary thyroid cancer in cancer survivors. Sci. Rep. 14, (2024).","DOI":"10.1038\/s41598-024-63155-z"},{"key":"2676_CR26","doi-asserted-by":"crossref","unstructured":"Gao, T. et al. Association between chemotherapy for surgically treated rectal cancer and second primary endometrial cancer. Sci. Rep. 14, (2024).","DOI":"10.1038\/s41598-024-69357-9"},{"key":"2676_CR27","doi-asserted-by":"crossref","unstructured":"GOREN, M. A. R. S. H. A. L. L. P., MD, R. E. B. A. K., WRIGHT, P. H. D. & HOROWITZ, M. A. R. C. E. M.D. AND CHARLES B. PRATT (M.D.: Cancer Chemotherapy-Induced Tubular Nephrotoxicity Evaluated by Immunochemical Determination of Urinary Adenosine Deaminase Binding Protein, 1986).","DOI":"10.1093\/ajcp\/86.6.780"},{"key":"2676_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2478\/jtim-2018-0007","volume":"6","author":"J Mohri","year":"2018","unstructured":"Mohri, J. et al. Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. J. Translational Intern. Med. 6, 32\u201337 (2018).","journal-title":"J. Translational Intern. Med."},{"key":"2676_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","volume":"8","author":"F Ries","year":"1986","unstructured":"Ries, F. & Klastersky, J. Nephrotoxicity induced by Cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 8, 368\u2013379 (1986).","journal-title":"Am. J. Kidney Dis."},{"key":"2676_CR30","doi-asserted-by":"crossref","unstructured":"Charles, G., Moertel, M. B. D., Archie, H. & Baggenstoss.: MULTIPLE PRIMARY MALIGNANT NEOPLASMS II. Tumors of different tissues or organs. CANCER 14, March - April 1961.","DOI":"10.1002\/1097-0142(196103\/04)14:2<231::AID-CNCR2820140203>3.0.CO;2-2"},{"key":"2676_CR31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.33314\/jnhrc.v17i4.1042","volume":"17","author":"B Shrestha","year":"2020","unstructured":"Shrestha, B. & Dunn, L. The declaration of Helsinki on medical research involving human subjects: A review of seventh revision. J. Nepal Health Res. Counc. 17, 548\u2013552 (2020).","journal-title":"J. Nepal Health Res. Counc."},{"key":"2676_CR32","doi-asserted-by":"crossref","unstructured":"Wen, B. et al. The 2024 Revision of the Declaration of Helsinki: a Modern Ethical Framework for Medical Research (Postgraduate Medical Journal, 2024).","DOI":"10.1093\/postmj\/qgae181"},{"key":"2676_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ctrv.2018.05.008","volume":"68","author":"AJM Rombouts","year":"2018","unstructured":"Rombouts, A. J. M. et al. Does pelvic radiation increase rectal cancer incidence? \u2013 A systematic review and meta-analysis. Cancer Treat. Rev. 68, 136\u2013144 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"2676_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ijrobp.2014.10.040","volume":"91","author":"A Berrington de Gonzalez","year":"2015","unstructured":"Berrington de Gonzalez, A. et al. Risk of second cancers according to radiation therapy technique and modality in prostate Cancer survivors. Int. J. Radiation Oncology*Biology*Physics. 91, 295\u2013302 (2015).","journal-title":"Int. J. Radiation Oncology*Biology*Physics"},{"key":"2676_CR35","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1634\/theoncologist.2019-0266","volume":"25","author":"H Jia","year":"2020","unstructured":"Jia, H. et al. Second primary malignancies in patients with colorectal cancer: A Population-Based analysis. Oncologist 25, e651\u2013e658 (2020).","journal-title":"Oncologist"},{"key":"2676_CR36","doi-asserted-by":"crossref","unstructured":"Little, J. B. Radiation carcinogenesis. Carcinogenesis vol.21 (2000).","DOI":"10.1093\/carcin\/21.3.397"},{"key":"2676_CR37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","volume":"86","author":"A de Berrington","year":"2013","unstructured":"de Berrington, A. et al. Second solid cancers after radiation therapy: A systematic review of the epidemiologic studies of the radiation Dose-Response relationship. Int. J. Radiation Oncology*Biology*Physics. 86, 224\u2013233 (2013).","journal-title":"Int. J. Radiation Oncology*Biology*Physics"},{"key":"2676_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djad040","volume":"115","author":"KJ Kim","year":"2023","unstructured":"Kim, K. J. et al. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer. JNCI: J. Natl. Cancer Inst. 115, 695\u2013702 (2023).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"2676_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrc2677","volume":"9","author":"L Mullenders","year":"2009","unstructured":"Mullenders, L. et al. Assessing cancer risks of low-dose radiation. Nat. Rev. Cancer. 9, 596\u2013604 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2676_CR40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jcp.2005.026062","volume":"58","author":"AMR Taylor","year":"2005","unstructured":"Taylor, A. M. R. Molecular pathology of ataxia telangiectasia. J. Clin. Pathol. 58, 1009\u20131015 (2005).","journal-title":"J. Clin. Pathol."},{"key":"2676_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.semradonc.2017.04.001","volume":"27","author":"DE Citrin","year":"2017","unstructured":"Citrin, D. E. & Mitchell, J. B. Mechanisms of normal tissue injury from irradiation. Semin. Radiat. Oncol. 27, 316\u2013324 (2017).","journal-title":"Semin. Radiat. Oncol."},{"key":"2676_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly, L. E. et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer. 116, 310\u2013317 (2017).","journal-title":"Br. J. Cancer"},{"key":"2676_CR43","unstructured":"Lindsay, M. et al. MD, MSCE: The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and Adults. American Society of Clinical Oncology Educational Book Volume 34, Number 1, (2014)."},{"key":"2676_CR44","doi-asserted-by":"crossref","unstructured":"Vardiman, J. W. The World Health Organization (WHO) Classification of Tumors of the Hematopoietic and Lymphoid Tissues: an Overview with Emphasis on the Myeloid Neoplasms (Chemico-Biological Interactions, 2009).","DOI":"10.1016\/j.cbi.2009.10.009"},{"key":"2676_CR45","doi-asserted-by":"crossref","unstructured":"Dracham, C. B., Shankar, A. & Madan, R. Radiation induced secondary malignancies: a review Article. Radiation Oncol. J., (2018).","DOI":"10.3857\/roj.2018.00290"},{"key":"2676_CR46","doi-asserted-by":"crossref","unstructured":"Ellis, N. A. et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, (2008).","DOI":"10.1182\/blood-2007-11-126508"},{"key":"2676_CR47","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10552-016-0790-x","volume":"27","author":"T-M Kuo","year":"2016","unstructured":"Kuo, T-M. & Mobley, L. R. How generalizable are the SEER registries to the cancer populations of the USA? Cancer Causes Control. 27, 1117\u20131126 (2016).","journal-title":"Cancer Causes Control"},{"key":"2676_CR48","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1002\/cncr.35535","volume":"130","author":"A Martin","year":"2024","unstructured":"Martin, A. et al. A guide to large data sets for population-based cancer research: strengths, limitations, and pitfalls. Cancer 130, 3802\u20133814 (2024).","journal-title":"Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02676-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02676-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02676-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:19:31Z","timestamp":1748488771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02676-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02676-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18782"}}